Vyvanse Adolescent Open-Label Safety and Efficacy Extension Study

Completed · Phase 3

Conditions studied: ADHD

In brief

The primary objective of this study is to evaluate the long-term safety of LDX administered as a daily morning dose (30, 50, and 70 mg/day) in the treatment of adolescents (13-17 years of age inclusive at the time of consent).

Key facts

Study ID
NCT00764868
Run by
Shire
People needed
269
Starts
2008-11-13
Expected to finish
2010-04-22
Last updated by the study team
2021-06-14

Who can join

Age: 13 and older, up to 17. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.